MARKET

HBIO

HBIO

Harvard Biosci
NASDAQ
3.690
-0.030
-0.81%
After Hours: 3.690 0 0.00% 16:02 04/24 EDT
OPEN
3.710
PREV CLOSE
3.720
HIGH
3.750
LOW
3.660
VOLUME
63.56K
TURNOVER
0
52 WEEK HIGH
6.29
52 WEEK LOW
3.600
MARKET CAP
160.22M
P/E (TTM)
-45.8385
1D
5D
1M
3M
1Y
5Y
Watch These 5 Technology Stocks for Q1 Earnings: Beat or Miss?
NASDAQ · 2d ago
Weekly Report: what happened at HBIO last week (0415-0419)?
Weekly Report · 2d ago
Harvard Bioscience Inc <HBIO.OQ> expected to post earnings of 2 cents a share - Earnings Preview
Harvard Bioscience Inc expected to post earnings of 2 cents a share. The company is expected to show a fall in quarterly revenue to $25.793 million from $29.98 million. The average analyst estimate is for the company to report a 14.0% decrease in revenue.
Reuters · 5d ago
Weekly Report: what happened at HBIO last week (0408-0412)?
Weekly Report · 04/15 09:51
Harvard Bioscience announces labor force reduction
Healthcare Harvard Bioscience announces labor force reduction. Company expects to realize annual run rate savings of approximately $4M beginning in the second quarter of 2024. The company also expects second quarter restructuring-related charges of about $0.5M. Harvard bioscience (NASDAQ:HBIO) stock.
Seeking Alpha · 04/09 13:28
HARVARD BIOSCIENCE INC: LABOR FORCE REDUCTION TO IMPROVE ITS OPERATING COST STRUCTURE AND SUPPORT ITS ONGOING INVESTMENTS IN GROWTH
Reuters · 04/09 13:00
Weekly Report: what happened at HBIO last week (0401-0405)?
Weekly Report · 04/08 09:53
Weekly Report: what happened at HBIO last week (0325-0329)?
Weekly Report · 04/01 09:53
More
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.

Webull offers Harvard Bioscience, Inc. stock information, including NASDAQ: HBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HBIO stock methods without spending real money on the virtual paper trading platform.